Posted by Michael Wonder on 11 Mar 2021
Kadmon announces U.S. FDA has extended the review period for belumosudil in chronic graft versus host disease
10 March 2021 - Kadmon today announced that the U.S. FDA has extended the review period for the new drug application for belumosudil for the treatment of chronic graft versus host disease.
In a notice received from the FDA on 9 March 2021, the Company was informed that the PDUFA goal date has been extended to 30 August 2021.
